1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

  • All
    • Last 3 Months
About 300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024

  • $ 3000
  • May 2020
  • 195 pages

Global Immuno-Oncology Market, By Major Indications ##. ## Head & Neck Cancer ##. ## Lung Cancer ##. ## Melanoma ##. ## Lymphoma ##. ## Leukemia ##. ## Others ##.

  • Lymphoma
  • Oncology
  • Therapy
  • World
  • Market Size

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024

  • $ 2500
  • June 2020
  • 120 pages

Our anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas: • Anaplastic lymphoma kinase (ALK) inhibitors market sizing • Anaplastic lymphoma kinase (ALK) inhibitors market forecast • Anaplastic lymphoma kinase (ALK) inhibitors market

  • Lymphoma
  • Therapy
  • Forecast

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

  • $ 2850
  • May 2020
  • 100 pages

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030 ##.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • Germany

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

  • $ 4750
  • May 2020
  • 200 pages

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stag

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Pathology
  • United States

Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)

  • $ 900
  • June 2020
  • 82 pages

B-cell lymphomas can be categorized into aggressive NHL, such as diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and burkitt' s lymphoma (BL), and indolent NHL, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • World
  • AbbVie Inc.

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • North America
  • United States

Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027

  • $ 3300
  • June 2020
  • 1500 pages

Lymphoma (Million Cells/ Kg), May’2020 Figure ##-##: Kymriah - Annual Sales Value (US$ Million), 2017 - 2019 Figure ##-##: Global - Kymriah Quarterly Sales Value (US$ Million), 2019 Figure ##-##: Yescarta – FDA Approval & US Patent Expiration Year Figure ##-##: US – Yescarta Target

  • Biopharmaceutical
  • Cell Therapy
  • Lymphoma
  • Medical Biotechnology
  • World

Umbilical Cord Blood Banking Market Research Report by Storage, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 3949
  • July 2020
  • 230 pages

Lymphoma ##. ##.

  • Lymphoma
  • Medical Biotechnology
  • United States
  • World
  • Market Size

Oral Cancer Treatment Market Research Report by Product Type, by Treatment, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 3949
  • July 2020
  • 231 pages

Lymphomas ##. ##.

  • Cancer
  • Lymphoma
  • Oropharynx Cancer
  • United States
  • Market Size

Global Oncology Partnering 2014-2020: Deal trends, players and financials

  • $ 3495
  • May 2020
  • 2500 pages

Lymphoma, Hodgkin’s lymphoma, Non Hodgkin’s lymphoma, Melanoma, Mesothelioma, Metastases, Bone metastases, Multiple myeloma, Neuroblastoma, Non-melanoma skin cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Renal cell carcinoma, Sarcoma, Solid tumors, Testicular cancer, Thyroid c

  • Lymphoma
  • Orphan Disease
  • Pharmaceutical
  • Therapy
  • United States

Hodgkin’s Lymphoma - Opportunity Analysis and Forecasts to 2029

  • $ 10995
  • June 2020
  • 140 pages

M. (2019) CANCER, LYMPHOMA, HODGKIN, STATPEARLS.

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Forecast

Global Hematology Partnering 2010-2020: Deal trends, players and financials

  • $ 3495
  • June 2020
  • 400 pages

Lymphoma Research, Leukemia & Lymphoma Society, Lev Pharmaceuticals, LFB Biomedicaments, LFB Biotechnologies, LifeHealth, Ligand Pharmaceuticals, Lonza, Loop Medical, LUNAC Therapeutics, Mallinckrodt Pharmaceuticals, MannKind Biopharmaceuticals, Mantecorp, Maruho, Masimo, Massa

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Demand

Global Diagnostics Partnering Terms and Agreements 2014-2020

  • $ 3495
  • May 2020
  • 1000 pages

Lymphoma Society, LG Life Sciences, Lonza, Lumos Pharma, Lupagen, MAB Discovery, Mabion, MabVax Therapeutics, mAbXience, Macquarie University, Macrogenics, Mapp Biopharmaceutical, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, MedImmune, Medison Pharma, Medivation,

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • United States

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020

  • $ 3495
  • May 2020
  • 300 pages

Hussman Foundation, Johns Hopkins University, Johnson & Johnson Innovation, JSC Binnopharm, JSC Pharmadis, Juvaris BioTherapeutics, KAEL-GemVax, KellBenx, Kindred Bio, Leukaemia & Lymphoma Research, LG Life Sciences, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, London

  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • United States

Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020

  • $ 3495
  • May 2020
  • 450 pages

Lymphoma Research, Leukocare, LG Life Sciences, LineaRx, Los Angeles Biomedical Research Institute, Louisiana State University, Lumos Pharma, Lund University, Lung Cancer Research Foundation, MabVax Therapeutics, Madison Vaccines, Massachusetts General Hospital, Matrivax, Mayo Clinic, MBF T

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Vaccine
  • United States

Global Proteomics Partnering Terms and Agreements 2010 to 2020

  • $ 3495
  • June 2020
  • 400 pages

Lymphoma Society, LifeArc, LifeMap Sciences, Life Technologies, Ligand Pharmaceuticals, Link Medicine, Lipimetix, LipimetiX Development, Lonza, Loreal, Lucigen, Lundbeck, Luxembourg Institute of Health, Magellan Biosciences, Maine Manufacturing, Margaret Q Landenberger Research Foundation,

  • Lymphoma
  • Pharmaceutical
  • Proteomics
  • Therapy
  • United States

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020

  • $ 3495
  • June 2020
  • 500 pages

Lymphoma Society, LG Life Sciences, Libbs Farmaceutica, LifeArc, Ligand Pharmaceuticals, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lonza, Lpath, Lumos Pharma, Lupagen, Lupin, Lupus Therapeutics, MAB Discovery, Mabion, MabQuest, MAbSilico, Mabspace Bioscience, MabVax Therapeuti

  • Lymphoma
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • United States
View report >

Cancer Statistics in Texas (USA)

  • June 2020
  • 20 pages

Among this group, leukemias are the most common cancers, followed by brain and central nervous system cancers, lymphomas, soft tissue sarcomas, and neuroblastoma.

  • Cancer
  • Lymphoma
  • Pathology
  • United States
  • Forecast

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on